Association of abnormal methylation of CpG islands in promoter domains of multiple tumor suppressor genes with non-small cell lung cancer

Chinese Journal of Clinical Oncology

Volumn 37, Issue 19, 2010, Pages 1109-1114

  Jin, Yongtang ^a   Xu, Heyun ^a   Zhang, Chenye ^a   Zhang, Hu ^a   Xue, Saoli ^b   Yu, Zaicheng ^b   Xu, Yingchun ^c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Methylation; Non small cell lung cancer (NSCLC); Tumor suppressor gene (TSG)

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETINOIC ACID RECEPTOR BETA; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; PROMOTER REGION; RISK FACTOR; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 78349234989     PISSN: 16727118     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1000-8179.2010.19.008     Document Type: Article

References (12)

1. Liu Y, Lan Q, Siegfried JM, et al. Aberrant promoter methylation of p16 and MGMT genes on lung tumors from smoking and never-smoking lung cancer patients[J]. Neoplasia, 2006, 8(1): 46-51.
2. Herman, JG, Graff, JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands[J]. Proc Natl Acad Sci U S A, 1996, 93(18): 9821-9826.
3. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer[J]. Nat Rev Genet, 2002, 3(6): 415-428.
4. Zochbauer-Muller S, Fong KM, Virmani AK, et al. Aberrant promoter methylation of multiple genes in non-small cell lung cancers [J]. Cancer Res, 2001, 61(1): 249-255.
5. Esteller M, Com PG, Baylin SB, et al. A gene hypermethylation profile of human cancer[J]. Cancer Res, 2001, 61(8): 3225-3229.
6. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors[J]. Mol Cancer Ther, 2001, 1(1): 61-67.
7. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer[J]. Clin Cancer Res, 2004, 10(7): 2284-2288.
8. Fujiwara K, Fujimoto N, Tabata M, et al. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer[J]. Clin Cancer Res, 2005, 11(3): 1219-1225.
9. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers[J]. J Natl Cancer Inst, 1997, 89(18): 1366-1373.
10. Toyooka S, Tokumo M, Shigematsu H, et al. Mutational and epigenetic evidence for independent for pathways for lung adenocarcinomas arising in smokers and never smokers[J]. Cancer Res, 2006, 66(3): 1371-1375.
11. Divine KK, Pulling LC, Marron-Terada PG, et al. Multiplicity of abnormal promoter methylation in lung adenocarcinomas from smokers and never smokers[J]. Int J Cancer, 2005, 114(3): 400-405.
12. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer[J]. Oncogene, 2001, 20(14): 1765-1770.